Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CELG
- CUSIP: 15102010
- Web: www.celgene.com
- Market Cap: $91.15 billion
- Outstanding Shares: 780,824,000
- 50 Day Moving Avg: $121.75
- 200 Day Moving Avg: $119.75
- 52 Week Range: $94.42 - $127.64
Sales & Book Value:
- Trailing P/E Ratio: 43.84
- Foreward P/E Ratio: 13.25
- P/E Growth: 0.78
- Annual Revenue: $11.68 billion
- Price / Sales: 7.80
- Book Value: $9.79 per share
- Price / Book: 11.92
- EBIDTA: $4.11 billion
- Net Margins: 17.80%
- Return on Equity: 77.95%
- Return on Assets: 16.00%
- Debt-to-Equity Ratio: 2.44%
- Current Ratio: 3.61%
- Quick Ratio: 3.42%
- Average Volume: 3.53 million shs.
- Beta: 1.74
- Short Ratio: 2
Frequently Asked Questions for Celgene (NASDAQ:CELG)
What is Celgene's stock symbol?
Celgene trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene's stock split? How did Celgene's stock split work?
Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.
How were Celgene's earnings last quarter?
Celgene Co. (NASDAQ:CELG) issued its earnings results on Thursday, April, 27th. The company reported $1.68 earnings per share for the quarter, beating analysts' consensus estimates of $1.47 by $0.21. The company earned $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. Celgene had a return on equity of 77.95% and a net margin of 17.80%. The business's revenue for the quarter was up 17.8% on a year-over-year basis. During the same period last year, the company earned $1.32 earnings per share. View Celgene's Earnings History.
When will Celgene make its next earnings announcement?
What guidance has Celgene issued on next quarter's earnings?
Celgene updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $7.15-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.21. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.26 billion.
Where is Celgene's stock going? Where will Celgene's stock price be in 2017?
25 brokerages have issued twelve-month price targets for Celgene's stock. Their predictions range from $98.00 to $162.00. On average, they anticipate Celgene's stock price to reach $139.59 in the next year. View Analyst Ratings for Celgene.
What are analysts saying about Celgene stock?
Here are some recent quotes from research analysts about Celgene stock:
- 1. Cann analysts commented, "Celgene unexpectedly reported that Teva submitted an ANDA for Pomalyst, which it intends to defend against. Based on an analysis of Celgene’s patents for Pomalyst, we found that patent lives extend out to 2031. However, Celgene’s documents indicate the date is 2024. We believe this is because Celgene thinks there is an important patent expiring on this date." (4/4/2017)
- 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to drive revenues at the company. Revlimid continued to outperform on the back of market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. Both Otezla and Pomalyst achieved blockbuster status in 2016 recording over $1 billion in sales. Meanwhile, Celgene continues to progress with its label expansion efforts and pipeline development. Label expansion of approved drugs would boost its revenues. Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. Fourth-quarter results were disappointing but the company’s outlook for 2017 was encouraging. Shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid for growth. Stiff competition in target markets is another concern." (3/9/2017)
- 3. Robert W. Baird analysts commented, "Celgene reported positive top-line data from the SUNBEAM trial of ozanimod in multiple sclerosis. Though no numbers were provided, it looks like the primary and key secondary endpoints were met, with a similar safety profile versus the Phase 2 studies. Though we find the lack of additional safety issues encouraging, success also depends on ability to compete with Gilenya, Tecfidera, and Roche's Ocrevus on efficacy. More complete data won't be available until later this half." (2/17/2017)
- 4. Jefferies Group LLC analysts commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class medium-term growth from healthy core franchises. We expect continued strong execution throughout the year and lower-risk catalysts to drive appreciation towards levels reflecting underappreciated prospects of their products and portfolio." (1/27/2017)
Are investors shorting Celgene?
Celgene saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 8,961,078 shares, an increase of 0.4% from the March 31st total of 8,925,832 shares. Based on an average daily volume of 3,026,120 shares, the days-to-cover ratio is currently 3.0 days.
Who are some of Celgene's key competitors?
Some companies that are related to Celgene include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), Kite Pharma (KITE), BIO-TECHNE Corp (TECH) and Galapagos NV (GLPG).
Who owns Celgene stock?
Celgene's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.87%), Vanguard Group Inc. (6.65%), State Street Corp (4.16%), Jennison Associates LLC (1.70%), FMR LLC (1.52%) and Bank of New York Mellon Corp (1.30%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Thomas O Daniel. View Institutional Ownership Trends for Celgene.
Who sold Celgene stock? Who is selling Celgene stock?
Celgene's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Winslow Capital Management LLC, Parametric Portfolio Associates LLC, Renaissance Technologies LLC, Janus Capital Management LLC, Marshall Wace LLP and TCW Group Inc.. Company insiders that have sold Celgene stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene.
Who bought Celgene stock? Who is buying Celgene stock?
Celgene's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of Montreal Can, Investec Asset Management LTD, OppenheimerFunds Inc., Wellington Management Group LLP, State Street Corp and Pioneer Investment Management Inc.. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene.
How do I buy Celgene stock?
Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Celgene stock cost?
One share of Celgene stock can currently be purchased for approximately $116.74.
Earnings History for Celgene (NASDAQ:CELG)Earnings History by Quarter for Celgene (NASDAQ:CELG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/26/2017|| || || || || || || || |
|4/27/2017||Q1 2017||$1.47||$1.68||$3.04 billion||$2.96 billion||View||N/A|
|1/26/2017||Q416||$1.59||$1.61||$3.03 billion||$2.98 billion||View||N/A|
|10/27/2016||Q316||$1.31||$1.58||$2.84 billion||$2.98 billion||View||Listen|
|7/28/2016||Q216||$1.39||$1.44||$2.70 billion||$2.74 billion||View||Listen|
|4/28/2016||Q116||$1.29||$1.32||$2.59 billion||$2.51 billion||View||Listen|
|1/28/2016||Q415||$1.22||$1.18||$2.54 billion||$2.54 billion||View||Listen|
|11/5/2015||Q315||$1.09||$1.23||$2.40 billion||$2.33 billion||View||N/A|
|7/23/2015||Q215||$1.08||$1.23||$2.24 billion||$2.28 billion||View||Listen|
|4/30/2015||Q115||$0.93||$0.95||$2.11 billion||$2.08 billion||View||N/A|
|1/29/2015||Q414||$0.88||$0.91||$2.08 billion||$2.09 billion||View||N/A|
|10/23/2014||Q314||$0.82||$0.97||$1.96 billion||$1.96 billion||View||Listen|
|7/24/2014||Q214||$0.77||$0.80||$1.85 billion||$1.87 billion||View||N/A|
|4/24/2014||Q114||$1.65||$1.67||$1.77 billion||$1.71 billion||View||N/A|
|1/30/2014||Q413||$1.54||$1.51||$1.72 billion||$1.76 billion||View||Listen|
|10/24/2013||Q313||$1.54||$1.56||$1.64 billion||$1.67 billion||View||N/A|
|7/25/2013||Q2 2013||$1.44||$1.52||$1.54 billion||$1.56 billion||View||Listen|
|4/25/2013||Q1 2013||$1.35||$1.37||$1.47 billion||$1.43 billion||View||Listen|
|1/24/2013||Q4 2012||$1.31||$1.32||$1.45 billion||$1.42 billion||View||Listen|
Earnings Estimates for Celgene (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.68
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Celgene (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celgene (NASDAQ:CELG)
Insider Ownership Percentage: 0.97%Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Institutional Ownership Percentage: 77.68%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/1/2017||James J Loughlin||Director||Sell||9,250||$124.00||$1,147,000.00|| |
|3/30/2017||Gilla Kaplan||Director||Sell||14,033||$123.83||$1,737,706.39|| |
|3/1/2017||Rupert Vessey||Insider||Sell||4,000||$124.42||$497,680.00|| |
|11/9/2016||Michael A Friedman||Director||Sell||18,600||$116.10||$2,159,460.00|| |
|10/24/2016||Corp /De/ Celgene||Major Shareholder||Buy||800,150||$14.00||$11,202,100.00|| |
|10/3/2016||Michael A Friedman||Director||Sell||56,116||$103.66||$5,816,984.56|| |
|9/23/2016||Richard W Barker||Director||Sell||20,000||$110.82||$2,216,400.00|| |
|9/15/2016||Gilla Kaplan||Director||Sell||9,710||$106.44||$1,033,532.40|| |
|8/23/2016||James J Loughlin||Director||Sell||27,500||$114.10||$3,137,750.00|| |
|8/22/2016||Michael D Casey||Director||Sell||43,134||$114.01||$4,917,707.34|| |
|7/28/2016||Robert J Hugin||Insider||Sell||100,000||$110.00||$11,000,000.00|| |
|6/20/2016||Robert J Hugin||Insider||Sell||75,000||$100.16||$7,512,000.00|| |
|4/4/2016||Gilla Kaplan||Director||Sell||15,967||$101.84||$1,626,079.28|| |
|3/3/2016||Michael W Bonney||Director||Buy||2,000||$103.01||$206,020.00|| |
|2/22/2016||James J Loughlin||Director||Sell||2,100||$104.12||$218,652.00|| |
|12/28/2015||Ernest Mario||Director||Sell||40,000||$119.36||$4,774,400.00|| |
|12/23/2015||Michael D Casey||Director||Sell||20,000||$122.11||$2,442,200.00|| |
|12/21/2015||Gilla Kaplan||Director||Sell||14,464||$110.62||$1,600,007.68|| |
|9/10/2015||Gilla Kaplan||Director||Sell||15,000||$122.45||$1,836,750.00|| |
|9/8/2015||Michael D. Casey||Director||Sell||15,000||$121.76||$1,826,400.00|| |
|7/13/2015||Thomas O Daniel||Insider||Sell||30,156||$120.78||$3,642,241.68|| |
|6/10/2015||Gilla Kaplan||Director||Sell||15,000||$111.74||$1,676,100.00|| |
|6/9/2015||Michael D Casey||Director||Sell||15,000||$111.18||$1,667,700.00|| |
|2/26/2015||Gilla Kaplan||Director||Sell||15,000||$122.89||$1,843,350.00|| |
|2/6/2015||Mark J Alles||Insider||Sell||117,099||$120.68||$14,131,507.32|| |
|1/15/2015||Lawrence V Stein||Insider||Sell||26,666||$120.01||$3,200,186.66|| |
|1/2/2015||Gilla Kaplan||Director||Sell||45,536||$113.47||$5,166,969.92|| |
|12/8/2014||Gilla Kaplan||Director||Sell||15,000||$118.20||$1,773,000.00|| |
|11/3/2014||Robert J Hugin||Insider||Sell||158,000||$106.68||$16,855,440.00|| |
|10/27/2014||Ernest Mario||Director||Sell||100,000||$102.85||$10,285,000.00|| |
|10/24/2014||Michael D Casey||Director||Sell||15,000||$102.94||$1,544,100.00|| |
|9/8/2014||Gilla Kaplan||Director||Sell||30,000||$93.73||$2,811,900.00|| |
|8/4/2014||Perry A Karsen||Insider||Sell||39,104||$87.55||$3,423,555.20|| |
|7/25/2014||Richard W Barker||Director||Sell||17,600||$87.03||$1,531,728.00|| |
|5/1/2014||Perry Karsen||Insider||Sell||11,922||$146.78||$1,749,911.16|| |
|3/4/2014||Michael Casey||Director||Sell||12,770||$162.33||$2,072,954.10|| |
|2/5/2014||Ernest Mario||Director||Sell||13,500||$151.87||$2,050,245.00|| |
|12/23/2013||Lawrence Stein||Insider||Sell||12,062||$168.19||$2,028,707.78|| |
|10/25/2013||Carrie Smith Cox||Director||Sell||18,750||$157.67||$2,956,312.50|| |
|9/4/2013||Gilla Kaplan||Director||Sell||15,000||$143.92||$2,158,800.00|| |
|8/28/2013||Thomas Daniel||Insider||Sell||32,263||$137.06||$4,421,966.78|| |
|8/2/2013||Perry A Karsen||Insider||Sell||93,008||$146.50||$13,625,672.00|| |
|5/30/2013||Robert J Hugin||Insider||Sell||68,087||$123.58||$8,414,191.46|| |
|5/29/2013||Ernest Mario||Director||Buy||1,000||$123.72||$123,720.00|| |
|5/28/2013||Thomas O Daniel||Insider||Sell||32,959||$124.91||$4,116,908.69|| |
Headline Trends for Celgene (NASDAQ:CELG)
Latest Headlines for Celgene (NASDAQ:CELG)
Celgene (CELG) Chart for Friday, May, 26, 2017